CNBX Pharmaceuticals Secures $45,000 Loan to Address Immediate Working Capital Needs

summarizeSummary

CNBX Pharmaceuticals Inc. secured a $45,000 non-convertible promissory note with a 20% repayment premium and 5% interest to fund immediate working capital, a critical move given its "going concern" status.

check_boxKey Events · Financing and Capital Events · CNBX

• Secured Promissory Note

  The company executed a non-convertible promissory note for $45,000 with 3i L.P. on March 10, 2026.

• Costly Financing Terms

  The note is due July 1, 2026, bears 5% simple interest, and requires a 20% premium on all payments, effectively increasing the repayment amount to $54,000 plus interest.

• Addresses Working Capital Needs

  Proceeds from the note will be used for immediate working capital and expenditures, addressing the company's critically low cash reserves and "going concern" warning.

• Future Financing Provisions

  The note includes optional exchange provisions into equity upon a future financing or redemption from future financing proceeds, indicating potential future capital raises.

auto_awesomeAnalysis · CNBX · Life Sciences

This filing is significant for CNBX Pharmaceuticals Inc. given its previously disclosed "going concern" warning and critically low cash reserves. The $45,000 non-convertible promissory note, while small in absolute terms, provides immediate working capital to extend the company's operational runway. However, the terms are costly, including a 20% premium on repayment and a 5% annual interest rate, reflecting the company's distressed financial position. The note also includes provisions for potential future equity conversion or redemption from future financings, indicating a reliance on further capital raises. This short-term financing is a critical step for survival but highlights ongoing financial challenges.